OBJECTIVE: To study human androgen receptor (hAR) mutations and their relationship to the clinical and pathological characteristics of patients with prostate cancer, as the mechanisms by which tumour cells escape androgen control and grow independently of hormone stimulation are unclear. PATIENTS AND METHODS: In all, 67 radical prostatectomy specimens were sequenced genomically (mean age of the patients, 64 years; median prostate-specific antigen level 15 ng/mL; 34% T1 and 66% T2). Of the 66 patients who had a valid follow-up, 28 (43%) had biochemical progression during the follow-up. RESULTS: There was mutation in the hAR in 11 patients (16%); nine types of different mutations were identified, only one of which was described previously in patients with prostate cancer. Patients with mutated hAR had statistically lower Gleason scores (P = 0.004) than had patients with native hAR. CONCLUSION: hAR mutations have a different effect on the disease course in patients with localized than in those with metastatic prostatic cancer.
OBJECTIVE: To study humanandrogen receptor (hAR) mutations and their relationship to the clinical and pathological characteristics of patients with prostate cancer, as the mechanisms by which tumour cells escape androgen control and grow independently of hormone stimulation are unclear. PATIENTS AND METHODS: In all, 67 radical prostatectomy specimens were sequenced genomically (mean age of the patients, 64 years; median prostate-specific antigen level 15 ng/mL; 34% T1 and 66% T2). Of the 66 patients who had a valid follow-up, 28 (43%) had biochemical progression during the follow-up. RESULTS: There was mutation in the hAR in 11 patients (16%); nine types of different mutations were identified, only one of which was described previously in patients with prostate cancer. Patients with mutated hAR had statistically lower Gleason scores (P = 0.004) than had patients with native hAR. CONCLUSION:hAR mutations have a different effect on the disease course in patients with localized than in those with metastatic prostatic cancer.
Authors: Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin Journal: Cancer Res Date: 2012-12-11 Impact factor: 12.701
Authors: Susan Evans-Axelsson; David Ulmert; Anders Örbom; Pernilla Peterson; Olle Nilsson; Johan Wennerberg; Joanna Strand; Karin Wingårdh; Tomas Olsson; Zandra Hagman; Vladimir Tolmachev; Anders Bjartell; Hans Lilja; Sven-Erik Strand Journal: Cancer Biother Radiopharm Date: 2012-04-10 Impact factor: 3.099
Authors: X Edward Zhou; Kelly M Suino-Powell; Jun Li; Yuanzheng He; Jeffrey P Mackeigan; Karsten Melcher; Eu-Leong Yong; H Eric Xu Journal: J Biol Chem Date: 2010-01-19 Impact factor: 5.157
Authors: Lisa M Lowenstein; Spyridon P Basourakos; Michelle D Williams; Patricia Troncoso; Justin R Gregg; Timothy C Thompson; Jeri Kim Journal: Nat Rev Clin Oncol Date: 2019-03 Impact factor: 66.675
Authors: Dong Han; Shuai Gao; Kevin Valencia; Jude Owiredu; Wanting Han; Eric de Waal; Jill A Macoska; Changmeng Cai Journal: Oncotarget Date: 2017-01-24